logo
Plus   Neg
Share
Email

Nektar To Withdraw NDA For Oxycodegol

Nektar Therapeutics (NKTR) said that it has decided to withdraw the New Drug Application or NDA for oxycodegol and to make no further investment into the program. Earlier, the U.S. Food and Drug Administration' Committees did not recommend approval of oxycodegol.

The company estimates that this will afford its cost savings of between $75 million to $125 million in 2020 based upon its projections of the estimated costs related to commercialization plans and post-approval studies previously discussed with the FDA.

The company said it is disappointed in the Committees' vote regarding oxycodegol and believes it is also disappointing for patients suffering from chronic pain and the physicians that treat those patients who are currently relying on existing opioid therapies.

NKTR closed Tuesday trading at $27.96, up $0.56 or 2.04%. But, in the after-hours, the stock dropped $4.28 or 15.31 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple is tracking iPhones that were stolen from its retail stores in recent days during the civil unrest, according to reports citing a warning message popping up on the stolen iPhones. Four current and former senior executives from two major broiler chicken producers, including Pilgrim's Pride CEO Jayson Penn, have been indicted for price fixing. Kezar Life Sciences, Inc. (KZR) - Shares of the clinical-stage biotechnology company soared nearly 80% after closing bell. The company's lead drug candidate is KZR-616, a selective inhibitor of immunoproteasome that plays a crucial role in the immune system. KZR-616 is under a phase Ib/II study in...
RELATED NEWS
Follow RTT